A pharmaceutical company is developing a new oral antibiotic. Preclinical studies suggest it has poor oral bioavailability due to extensive first-pass hepatic metabolism. Which investigation is most appropriate to confirm the extent of first-pass metabolism and to determine whether an intravenous formulation would be necessary for adequate systemic exposure?